SCHEMBL4519984

SCHEMBL4519984

CCOC(=O)CNC(=O)Nc1ccc(CC2CCN(C3CCCCC3)C2=O)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
EPHX2 P34913 2/20 0.40
NPC1 O15118 1/20 0.40
TSHR P16473 1/20 0.40
HSD11B1 P28845 1/20 0.39
ALDH1A1 P00352 4/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
P2RX7 Q99572 1/20 0.38
NLRP3 Q96P20 1/20 0.37
LMNA P02545 2/20 0.37
KDM4E B2RXH2 1/20 0.37
CCR3 P51677 2/20 0.36
USP2 O75604 1/20 0.36
HPGD P15428 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4516607 0.89 HSD11B1 (0.44) HTTRAB9ASMN1; SMN2EPHX2NPC1
SCHEMBL4519747 0.88 HSD11B1 (0.46) HTTRAB9ASMN1; SMN2EPHX2NPC1
SCHEMBL4527041 0.87 LMNA (0.46) SMN1; SMN2HSD11B1ALDH1A1MEN1GAA
SCHEMBL4506137 0.87 ALDH1A1 (0.51) HTTRAB9ASMN1; SMN2EPHX2NPC1
SCHEMBL4508949 0.84 HSD11B1 (0.43) HTTRAB9ASMN1; SMN2EPHX2NPC1
SCHEMBL4515294 0.84 HSD11B1 (0.43) HTTRAB9ASMN1; SMN2EPHX2NPC1
SCHEMBL4514812 0.81 ALDH1A1 (0.46) SMN1; SMN2HSD11B1ALDH1A1MEN1GAA
SCHEMBL4513595 0.80 HSD11B1 (0.46) SMN1; SMN2HSD11B1ALDH1A1KDM4EHPGD
SCHEMBL4509056 0.80 HSD11B1 (0.43) HSD11B1ALDH1A1MEN1GAAKMT2A
SCHEMBL4515140 0.80 HSD11B1 (0.45) SMN1; SMN2HSD11B1ALDH1A1P2RX7KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 HTT 3659/4885RAB9A 3524/4885SMN1; SMN2 4487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.